Anorexia nervosa Anorexia nervosa
Conditions
Sponsors
Sakuma Kenji
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The clinical trial will be described in detail to the individuals, and written informed consent will be obtained from all participants and their guardians 2. Individuals age: 18 >= years old and = 12 and = 10 mg/day in escitalopram equivalents) or antipsychotics (>= 3 mg/day in aripiprazole equivalents) with a sufficient dose for 4 weeks or more (failure to achieve a weight gain of >= 0.5 kg/week during the treatment period). We will confirm the result from their medical records. 6. Individuals who will not respond to inpatient treatment for 4 weeks or more (failure to achieve a weight gain of >= 0.5 kg/week during the treatment period). We will confirm the result from their medical records.
Exclusion criteria
Exclusion criteria: 1. Individuals with metal implants or devices close to the stimulation site (e.g., cochlear implants, surgical clips with magnetic properties, or neurostimulators such as deep brain stimulation or vagus nerve stimulation), individuals with a cardiac pacemaker 2. Individuals with metal implants or devices not close to the stimulation site (e.g., implanted medication pumps), titanium products in their heads, magnetic dentures/implants 3. Individuals with a history of seizures, a history of intracranial lesions at risk for seizures, individuals taking drugs that reduce seizure threshold (methylphenidate or ketamine), individuals with alcohol or stimulant use disorder or withdrawal, pregnant individuals, individuals with severe physical disease 4. Individuals with a history of receiving rTMS in the current depressive episode (with a diagnosis of major depressive disorder within the past 6 months) 5. Individuals in whom low body weight will be judged to be attributable to psychiatric disorders other than anorexia nervosa (including dementia, depression, bipolar disorder, schizophrenia, obsessive-compulsive disorder, anxiety disorders, autism spectrum disorder, and borderline personality disorder) or to organic diseases (including endocrine and metabolic disorders, gastrointestinal diseases, infections, and malignancies) 6. Individuals with unimproved low body weight due to poor adherence to pharmacological treatment 7. Individuals diagnosed with substance or medication-induced mood disorder 8. Individuals who will answer "yes" at baseline to the following questions: "Do you have any suicidal ideations although you do not have any plans for committing suicide? or "Do you have any suicidal ideations and any plans for committing suicide?" 9. Individuals judged to be inappropriate by researchers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in overall psychological symptoms of anorexia nervosa (change from baseline to week 4 in EDI-3 eating disorder risk composite score) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Change in overall psychological symptoms of anorexia nervosa (change from baseline to day 5-7, week 2, and 6 in EDI-3 eating disorder risk composite score) 2. Change in ineffectiveness (change from baseline to day 5-7, week 2, 4, and 6 in EDI-3 ineffectiveness composite score) 3. Change in interpersonal problems (change from baseline to day 5-7, week 2, 4, and 6 in EDI-3 interpersonal problems composite score) 4. Change in affective problems (change from baseline to day 5-7, week 2, 4, and 6 in EDI-3 affective problems composite score) 5. Change in overcontrol (change from baseline to day 5-7, week 2, 4, and 6 in EDI-3 overcontrol composite score) 6. Change in psychological maladjustment (change from baseline to day 5-7, week 2, 4, and 6 in EDI-3 global psychological maladjustment composite score) 7. Change in drive for thinness (change from baseline to day 5-7, week 2, 4, and 6 in EDI-3 drive for thinness subscale score) 8. Change in bulimia (change from baseline to day 5-7, week 2, 4, and 6 in EDI-3 bulimia subscale score) 9. Change in body dissatisfaction (change from baseline to day 5-7, week 2, 4, and 6 in EDI-3 body dissatisfaction subscale score) 10. Change in low self-esteem (change from baseline to day 5-7, week 2, 4, and 6 in EDI-3 low self-esteem subscale score) 11. Change in personal alienation (change from baseline to day 5-7, week 2, 4, and 6 in EDI-3 personal alienation subscale score) 12. Change in interpersonal insecurity (change from baseline to day 5-7, week 2, 4, and 6 in EDI-3 interpersonal insecurity subscale score) 13. Change in interpersonal alienation (change from baseline to day 5-7, week 2, 4, and 6 in EDI-3 interpersonal alienation subscale score) 14. Change in interoceptive deficits (change from baseline to day 5-7, week 2, 4, and 6 in EDI-3 interoceptive deficits subscale score) 15. Change in emotional dysregulation (change from baseline to day 5-7, week 2, 4, and 6 in EDI-3 emotional dysregulation subscale score) 16. | — |
Contacts
Public ContactKenji Sakuma
Fujita Health University Hospital
Outcome results
None listed